alexa Anthelminthic Activity Of Glibenclamide Against Experimental Cystic Echinococcosis
ISSN: 2155-9597

Journal of Bacteriology & Parasitology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd World Conference on Parasitology & Pathogenesis
July 12-13, 2017 Chicago, USA

Julia A. Loos, Valeria A. Davila, Andrea C. Cumino
Mar del Plata National University, Argentina
Posters & Accepted Abstracts: J Bacteriol Parasitol
DOI: 10.4172/2155-9597-C1-032
Statement of the Problem: Cystic echinococcosis is a worldwide parasitic zoonosis caused by the larval stage of Echinococcus granulosus. Current chemotherapy against this disease is based on benzimidazoles (BZMs). However, BZM treatment results in a low cure rate and causes side effects. Therefore, new treatment options are needed. The antidiabetic drug glibenclamide (Glb) is a second-generation sulfonylurea receptor inhibitor that has been shown to be active against protozoan parasites. The purpose of this study is to investigate the in vitro and in vivo pharmacological effects of Glb against the larval stage of E. granulosus. Methodology & Theoretical Orientation: Viable protoscoleces and metacestodes were cultured in vitro with different concentrations of Glb and/or ABZSO and mortality was calculated daily. Subsequently, E. granulosus-infected mice were orally treated with Glb and/or ABZ daily for 60 days. The hydatid cysts collected from the animals were weighed and analyzed by SEM. Findings: The in vitro Glb activity on both protoscoleces and metacestodes was dependent on the concentration. In addition, the combination of Glb and ABZSO had a greater effect on metacestodes than each drug alone. Likewise, a reduction of the cyst weight was also found after administration of Glb to infected mice. However, Glb + ABZ combined treatment not shown to be more effective than Glb monotherapy. Our results also demonstrated mitochondrial membrane depolarization and increase of Ca+2 intracellular levels in Glb-treated protoscoleces. Moreover, the intracystic drug accumulation, the competition of Glb for 1-NPN binding site in protoscoleces, and the bioinformatic analysis using the available E. granulosus genome, suggest the presence of genes encoding receptor and transporters of sulfonylureas in the parasite. Conclusion & Significance: Glb shows anthelmintic effect on E. granulosus larval stage. Further studies are needed to fully investigate the mechanism involved in the therapeutic response of the parasite to this sulfonylurea.

Julia A Loos has a PhD in Biological Science (National University of Mar del Plata, 2017) and she is currently working as a postdoc under the direction of Prof. Dr. Andrea Cumino. She has been serving as assistant teacher for subjects such as Histology, General Microbiology and Farmacology, that are part of the Biology, Biochemistry and Medicine courses of study. She participates in several research projects on Parasitology and has published original articles. Currently, her research is focused on the study of intermediary metabolism and energy control in the larval stage of Echinococcus spp.

Email: [email protected], [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version